Virax Biolabs (VRAX) Operating Leases (2024 - 2026)
Virax Biolabs (VRAX) posted quarterly Operating Leases of $304808.0 for Q1 2026, up 4.55% year-over-year from $291543.0 in Q1 2025, and up 4.55% quarter-over-quarter from $291543.0 in Q1 2025.
Virax Biolabs (VRAX) Operating Leases (2024 - 2026) Analysis & Trends
Virax Biolabs' Operating Leases history runs 3 years deep, the most recent figure standing at $304808.0 for Q1 2026.
- In Q1 2026, Operating Leases rose 4.55% year-over-year to $304808.0; the TTM figure through Mar 2026 stood at $304808.0 (up 4.55% YoY), while the FY2026 annual figure was $304808.0, up 4.55% from the prior year.
- Operating Leases for Q1 2026 stood at $304808.0, up from $291543.0 in the prior quarter.
- The five-year high for Operating Leases was $304808.0 in Q1 2026, with the low at $224300.0 in Q1 2024.
- The 3-year median for Operating Leases is $291543.0 (2025), against an average of $273550.3.
- The sharpest annual moves came in 2025 and 2026: Operating Leases increased 29.98% in 2025, then rose 4.55% in 2026.
- Virax Biolabs' Operating Leases stood at $224300.0 in 2024, then advanced by 29.98% to $291543.0 in 2025, then increased by 4.55% to $304808.0 in 2026.
- Business Quant data shows VRAX's Operating Leases at $304808.0 in Q1 2026, $291543.0 in Q1 2025, and $224300.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Virax Biolabs | 1.31 Mn | -5.13 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 304,808.00 |
| Mar 31, 2025 | 291,543.00 |
| Mar 31, 2024 | 224,300.00 |